Researchers at Stanford have identified polymorphisms in SIRPalpha that can be used to predict responsiveness to immunotherapy. Cancer cells can evade elimination by the immune system by expressing the CD47 "don't eat me" signal.
Researchers at Stanford have developed agents to enhance the therapeutic efficacy of a variety of anti-cancer therapeutics. Cell loss by apoptosis occurs in normal development and in tumor environments.
Researchers in Prof. Irving Weissman's laboratory have developed cell culture techniques to rapidly and efficiently derive pure populations of mesodermal cells from human pluripotent stem cells (hPSCs).
Researchers at Stanford have developed methods to promote bone healing in people with diabetes. Diabetes is a chronic metabolic disease associated with many clinical complications including impaired bone healing.
Researchers in Prof. Irving Weissman's lab have developed and patented antibodies and methods to prevent the formation of teratomas from human pluripotent stem cells used for regenerative medicine, cell therapy or research.
Researchers at Stanford have developed methods to identify, isolate, and use specific progenitor cell populations to generate adipose tissue and functional blood vessels in vivo.
A team of Stanford researchers have identified a skeletal stem cell (SSC) along with the protein factors needed to direct differentiation toward bone, cartilage or bone marrow stroma.